NCT03183219 is a Phase 1, PHASE2 clinical trial of Cryosurgery or IRE surgery in Liver Cancer, sponsored by Fuda Cancer Hospital, Guangzhou.

Who is sponsoring NCT03183219?

NCT03183219 is sponsored by Fuda Cancer Hospital, Guangzhou.

What drugs are being tested in NCT03183219?

Interventions in NCT03183219: Cryosurgery or IRE surgery, γδ T cell, γδ T cells/ A Cryosurgery or IRE.

What condition does NCT03183219 study?

NCT03183219 studies Liver Cancer.

Is NCT03183219 still recruiting?

NCT03183219 is currently completed. Last updated 13 July 2020.

Last reviewed 2020-07-13 · How we verify

NCT03183219

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficiency of γδ T Cell Against Liver Cancer

Completed Phase 1, PHASE2 Last updated 13 July 2020

What this trial tests

Phase 1, PHASE2 trial testing Cryosurgery or IRE surgery in Liver Cancer in 30 participants. Completed in 15 June 2019.

Timeline

15 June 2017

Primary endpoint
15 January 2018

15 June 2019

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	15 June 2017
Primary completion	15 January 2018
Estimated completion	15 June 2019
Sites	1 location across China

Drugs / interventions tested

Cryosurgery or IRE surgery
γδ T cell — full drug profile →
γδ T cells/ A Cryosurgery or IRE

Conditions studied

Liver Cancer — all drugs for Liver Cancer →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 18 to 75, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, effects of γδT cells on human Liver Cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y, Xiang Z, Alnaggar M, Kouakanou L, et al · · 2021 · cited 184× · PMID 32939032 · DOI 10.1038/s41423-020-0515-7
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
Yakkala C, Chiang CL, Kandalaft L, Denys A, et al · · 2019 · cited 67× · PMID 31608067 · DOI 10.3389/fimmu.2019.02283
The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.
Liu Y, Zhang C. · · 2020 · cited 55× · PMID 32413966 · DOI 10.3390/cells9051206
Cancer immunotherapy by γδ T cells.
Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B. · · 2024 · cited 48× · PMID 39361750 · DOI 10.1126/science.abq7248
Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
Smirnov S, Petukhov A, Levchuk K, Kulemzin S, et al · · 2021 · cited 27× · PMID 34975869 · DOI 10.3389/fimmu.2021.780145
Current Status of Gene Engineering Cell Therapeutics.
Saudemont A, Jespers L, Clay T. · · 2018 · cited 22× · PMID 29459866 · DOI 10.3389/fimmu.2018.00153
Gamma/delta T cells as cellular vehicles for anti-tumor immunity.
Wang CQ, Lim PY, Tan AH. · · 2023 · cited 19× · PMID 38274800 · DOI 10.3389/fimmu.2023.1282758

Verify or expand the search:

Other trials of Cryosurgery or IRE surgery

Trials testing the same drug.

NCT03183232 — Safety and Efficiency of γδ T Cell Against Lung Cancer · Phase 1, PHASE2 · completed

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183219 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 13 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183219.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing